X
Xiaokui Mo
Researcher at Ohio State University
Publications - 154
Citations - 5410
Xiaokui Mo is an academic researcher from Ohio State University. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 37, co-authored 139 publications receiving 4217 citations. Previous affiliations of Xiaokui Mo include National Cheng Kung University & James Cancer Hospital.
Papers
More filters
Journal ArticleDOI
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells
Xiaohua Zhu,Mohamed Badawi,Steven M. Pomeroy,Dhruvitkumar S. Sutaria,Zhiliang Xie,Alice Baek,Jinmai Jiang,Ola A. Elgamal,Xiaokui Mo,Krista M. D. La Perle,Jeffrey J. Chalmers,Thomas D. Schmittgen,Mitch A. Phelps +12 more
TL;DR: This study provides a framework for assessment of immunogenicity and toxicity that will be required as EVs from varying cell sources are tested within numerous animal models and eventually in humans.
Journal ArticleDOI
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
Rosa Lapalombella,Qingxiang Sun,Katie Williams,Larissa Tangeman,Shruti Jha,Yiming Zhong,Virginia M. Goettl,Emilia Mahoney,Caroline Berglund,Sneha V. Gupta,Alicia Farmer,Rajeswaran Mani,Amy J. Johnson,David M. Lucas,Xiaokui Mo,Dirk Daelemans,Vincent Sandanayaka,Sharon Shechter,Dilara McCauley,Sharon Shacham,Michael Kauffman,Yuh Min Chook,John C. Byrd +22 more
TL;DR: Evidence is presented that SINEs can restore normal regulation to the majority of the dysregulated pathways in CLL both in vitro and in vivo and induce apoptosis of CLL cells with a favorable therapeutic index, with enhanced killing of genomically high-risk Cll cells that are typically unresponsive to traditional therapies.
Journal ArticleDOI
Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis
Feng Geng,Xiang Cheng,Xiaoning Wu,Ji Young Yoo,Chunming Cheng,Jeffrey Yunhua Guo,Xiaokui Mo,Peng Ru,Brian Hurwitz,Sung Hak Kim,Jose Otero,Vinay K. Puduvalli,Etienne Lefai,Jianjie Ma,Ichiro Nakano,Craig Horbinski,Balveen Kaur,Arnab Chakravarti,Deliang Guo +18 more
TL;DR: It is unraveled that cholesterol esterification and LD formation are signature of GBM, and human patients with glioma possess elevated LDs that correlate with GBM progression and poor survival, and inhibiting SOAT1 to block cholesterol Esterification is a promising therapeutic strategy to treat GBM.
Journal ArticleDOI
Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10.
Jeffrey L. Voorhees,Andrew J. Tarr,Eric S. Wohleb,Jonathan P. Godbout,Xiaokui Mo,John F. Sheridan,Timothy D. Eubank,Clay B. Marsh +7 more
TL;DR: One of the first reports describing the biological and behavioral impact following prolonged RST is provided and details on the correlation between responses to chronic RST and those seen in depressive disorders are provided.
Journal ArticleDOI
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Kaushal Joshi,Yeshavanth Kumar Banasavadi-Siddegowda,Xiaokui Mo,Sung Hak Kim,Ping Mao,Cenk Kig,Diana Nardini,Robert W. Sobol,Lionel M.L. Chow,Harley I. Kornblum,Ronald R. Waclaw,Monique Beullens,Ichiro Nakano +12 more
TL;DR: The data indicate that FOXM1 signaling through its direct interaction with MELK regulates key mitotic genes in GSCs in a PLK1‐dependent manner and thus, this protein complex is a potential therapeutic target for GBM.